Characterization of in vivo acquired resistance of Mycoplasma hyopneumoniae to macrolides and lincosamides by Stakenborg, T et al.
290
MICROBIAL DRUG RESISTANCE
Volume 11, Number 3, 2005
© Mary Ann Liebert, Inc.
Characterization of In Vivo Acquired Resistance of
Mycoplasma hyopneumoniae to Macrolides and Lincosamides
TIM STAKENBORG,1 JO VICCA,2 PATRICK BUTAYE,1 DOMINIEK MAES,2 F. CHRIS MINION,3
JOHAN PEETERS,1 AART DE KRUIF,2 and FREDDY HAESEBROUCK2
ABSTRACT
Macrolides and related antibiotics are used to control mycoplasma infections in the pig industry worldwide.
Some porcine mycoplasmas, however, survive these treatments by acquiring resistance. The mechanism of ac-
quired resistance to macrolides and lincosamides was studied in more detail for Mycoplasma hyopneumoniae
by comparing both the phenotype and genotype of a resistant field isolate to five susceptible isolates. The MICs
were significantly higher for the resistant strain for all antibiotics tested. The MICs for the 16-membered
macrolide tylosin ranged from 8 to 16 g for the resistant strain and from 0.03 to 0.125 g/ml for the five sus-
ceptible strains. The MICs for the 15-membered macrolides and lincosamides were higher than 64 g/ml for
the resistant strain while only 0.06 to 0.5 g/ml for the susceptible strains. Mycoplasma hyopneumoniae strains
are intrinsically resistant to the 14-membered macrolides due to a G2057A transition (E. coli numbering) in
their 23S rDNA. Therefore, high MICs were observed for all strains, although the MICs for the resistant strain
were clearly increased. An additional, acquired A2058G point mutation was found in the 23S rRNA gene of
the resistant strain. No differences linked to resistance were found in the ribosomal proteins L4 and L22. The
present study showed that 23S rRNA mutations resulting in resistance to macrolides and lincosamides as de-
scribed in other Mycoplasma spp. also occur under field conditions in M. hyopneumoniae.
INTRODUCTION
MYCOPLASMAS ARE THE SMALLEST FREE-LIVING ORGANISMS,carrying no cell wall. As a consequence, they are natu-
rally resistant to antibiotics interfering with cell wall synthesis.
Additionally, a number of reports indicate a decrease in sus-
ceptibility of mycoplasmas against widely used antimicrobial
agents, including the macrolides, lincosamides, and strep-
togramins (MLS).2,12,15,25,35,37 MLS antibiotics have overlap-
ping binding sites on the 23S rRNA and, hence, related an-
timicrobial activities. By binding to domain V of the 23S rRNA,
they inhibit protein synthesis by means of blocking the path
through which nascent peptides exit the ribosome.28,33 Addi-
tional studies have mapped the recognition site of the 14-mem-
bered macrolide erythromycin and its derived ketolides to do-
main II and IV of the 23S rRNA as well.4,29,36
Bacterial species containing only one or two copies of
rRNA genes, like all Mycoplasma species, tend to use muta-
tions at bases 2,057–2,059 of the 23S rRNA as a way of ac-
quiring resistance.12,16 Some mycoplasmas, like M. hyopneu-
moniae, are intrinsically resistant to 14-membered macrolides
due to a G2057A transition in their 23S rDNA.12,20,30 Addi-
tional resistance to MLS antibiotics due to mutations at posi-
tions 2,609–2,611 has been observed for several bacterial
species.6,14,25 A mutation at position 2,062 was linked to re-
sistance against josamycin, a 16-membered macrolide, in an
in vitro-selected Mycoplasma hominis strain.11,16 For a num-
ber of other bacteria, mutations in the L4 and L22 binding
proteins were linked to MLS resistance.6,8,9,19,26,27,29,31
Nonetheless, acquired resistance to MLS in Mycoplasma
species is rarely documented or is induced in vitro rather than
observed in field isolates.
The aim of this study was to characterize fully both phe-
notypically and genetically the in vivo acquired resistance to
macrolides and lincosamides in a M. hyopneumoniae field 
isolate.
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MATERIALS AND METHODS
Media, bacterial isolates, and antibiotics
Isolates and media. The F2, F5, F6, F18, and F19 strains
were all Belgian M. hyopneumoniae field strains isolated from
lung tissue of fattening pigs collected at slaughterhouses. The
J strain (ATCC 25934) was used as a control strain. The Friis’
broth10 without added antibiotics was used to grow the M. hy-
opneumoniae strains.
Antibiotics. Erythromycin, tylosin, and clindamycin were ob-
tained from Sigma (UK). The other antibiotics were obtained
from the drug’s manufacturer as reference powder: lincomycin
and azithromycin were kindly supplied by Pfizer (NY), clar-
ithromycin by Abott (IL).
MIC test by a macro broth dilution technique. Antibiotic stock
solutions of 1,000 g/ml were freshly prepared the day of use
according to guidelines described by the National Committee for
Clinical Laboratory Standards (NCCLS).22 Clarithromycin, ery-
thromycin, and azithromycin were dissolved in a minimum
amount of ethanol and further diluted in water. All other antibi-
otics were directly dissolved in water. For each antimicrobial,
two-fold dilutions ranging from 0.015 g/ml to 64 g/ml were
prepared and each strain was tested twice. Broths were inocu-
lated with the M. hyopneumoniae strains, resulting in approxi-
mately 105 color-changing units (CCU) per ml in a final volume
of 2 ml. An additional tube contained only medium and was used
as a negative control, while a second tube without antibiotics
served as a positive control. The MIC was defined as the lowest
concentration of antimicrobial agent in which no growth of M.
hyopneumoniae was observed. Growth was detected by a color
change of the Phenol Red indicator from red to yellow due to
glucose fermentation. The test was ended when no more color
change in the tubes was visible during 2 consecutive days.
DNA sequencing of the L4- and L22-genes and
domain V of the 23S rDNA
To sequence the L4 and L22 proteins, primers were designed
based on the M. hyopneumoniae genome sequence of reference
strain 232.21 Primers for the amplification of domain V of the
23S rDNA were selected based on the M. hyopneumoniae
ATCC 27719 strain (GenBank accession number X68421). All
primers and reaction conditions used are listed in Table 1. Af-
ter purification of the PCR product on Microcon 100 columns
(Millipore, MA), both strands were sequenced on a CEQ8000
TABLE 1. SELECTED PRIMERS USED FOR THE AMPLIFICATION AND SEQUENCING OF THE 23S, L4, 
AND L22 GENES OF THE M. hyopneumoniae J REFERENCE AND FIELD STRAINS
Primer name Primer sequence (5→ 3) Number of cycles (cycle conditions)a
L4 FOR AGCATTCAAAGTCAGAAAAC 25 (30 sec at 94°C; 30 sec at 47.6°C; and 1 min at 72°C)
L4 REV GATTCTCTTCTCCAAATTAG
L22 FOR AGCAGTCGCTTCACTCAAAA 25 (30 sec at 94°C; 30 sec at 52.5°C; and 1 min at 72°C)
L22 REV ACCTCTTTTTCTTGCGCTAA
23S FOR GGTAGCGAAATTCCTTGTCA 25 (30 sec at 94°C; 30 sec at 55.2°C; and 1 min at 72°C)
23S REV GAGCAGCTCTCATCAATATTCC
aAll PCRs, unless stated otherwise, were performed using 2 U of recombinant Taq polymerase, 5 l of 10 PCR buffer, 75
nmol MgCl2, 10 nmol of each dNTP, and 10 pmol of both forward and reverse primer.
aSequences were extracted from Genbank. Accession numbers are: Escherichia coli, EC0278710; M. hominis, AF443617; M.
fermentans, AF422142; M. genitalium, U39634; M. pneumoniae, AE000007; M. gallisepticum, AE016968; M. penetrans,
AP004174; M. flocculare, MYC16SR; M. hyorhinis, AF121891; M. pulmonis, AL445565.
bNo differences in the 23S DNA of strain F2, F5, F6, F18, F23, and J were observed.
cResistance due to A2062 point mutations have been described elsewhere.10
FIG. 1. Multiple sequence alignment of the 23S rDNA of different Mycoplasma spp. compared to E. coli. Nucleotides related
to resistance to macrolides are presented in bold. The G2058A transition of the resistant M. hyopneumoniae F19 strain is under-
lined as well. 
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sequencer (Beckmann, UK) according to the manufacturer’s in-
structions. The sequences were aligned for further analysis us-
ing Clustal W (V1.82). The sequences of domain V of the 23S
rDNA of the M. hyopneumoniae strains were compared with
sequences of E. coli and other Mycoplasma species extracted
from GenBank (Fig. 1).
RESULTS
Because the isolates grew at different rates, not all MICs
were read on the same day. The J reference strain grew faster
than the other isolates, and the MICs of the antibiotics were
reached after approximately 5 days, whereas it took up to 1
week for the other strains. The MICs for the isolates are pre-
sented in Table 2. For each isolate, the MIC values of the repli-
cates were equal to or differed from each other by only one di-
lution. The MICs for erythromycin and clarithromycin ranged
from 8 to 32 g/ml for all strains tested, except for the resis-
tant F19 isolate. For this strain, the MIC values exceeded the
highest concentration (64 g/ml) tested. All isolates, except the
F19 strain, were also susceptible to the other antibiotics tested.
The MICs ranged from 0.06 to 0.25 g/ml for the 15-mem-
bered macrolide, azithromycin; from 0.03 to 0.125 g/ml for
the 16-membered macrolide, tylosin; and from 0.125 to 0.5
g/ml for the lincosamides, lincomycin, and clindamycin. The
MICs for the resistant isolate (F19) also exceeded the highest
concentration of 64 g/ml for these antibiotics, with the ex-
ception of tylosin (MICs ranging from 8 to 16 g/ml).
Sequence analysis of the 23S rDNA, as shown in Fig. 1,
demonstrates the intrinsic resistance of certain Mycoplasma spp.
to 14-membered macrolides due to a G2057A transition. An ac-
quired A2058G transition was found exclusively in the resis-
tant M. hyopneumoniae strain. Only a small number of differ-
ences were present in the L22 proteins (97% identity at DNA
level). Protein L4 proved very conserved (99% identical at
DNA level) as no amino acid substitutions were found between
any of the strains (data not shown).
DISCUSSION
Because M. hyopneumoniae strains are difficult to grow on
agar plates and colonies are hard to detect, a serial broth dilu-
tion technique using Friis’ medium was chosen to test for an-
tibiotic resistance. This technique, based on an earlier report of
Ter Laak et al.,34 was performed in duplicate and proved to be
reproducible.
The J reference strain seemed better adapted to the Friis’
medium and grew faster than the other isolates. This may ex-
plain the higher MICs, up to one dilution, for this strain. Nev-
ertheless, all individual MICs were very similar for the sus-
ceptible strains and clearly differed from those of the resistant
F19 strain. Moreover, MICs for the sensitive strains were con-
sistent with previous reports.18,32,34
Although M. hyopneumoniae strains are naturally resistant
to 14-membered macrolides due to a G2057A transition of the
23S gene,36 even higher MICs were observed for the resistant
strain. This increased resistance may well be explained by the
observed A2058G transition because footprinting patterns ex-
amining the drug binding sites in other bacteria identified these
specific nucleotides.7,17 Hence, a lower affinity of the drugs to
the 23S rRNA, due to the acquired mutation, results in a de-
creased antimicrobial activity. Apart from this increased insen-
sitivity to erythromycin and clarithromycin, the F19 field iso-
late proved also resistant to all other antibiotics tested. This is
in agreement with earlier reports in other bacterial species
where mutations at position 2,058 led to high MLS resistant
strains.7,36 This A2058G transition may even be the most fre-
quently observed substitution in vivo in association with MLS
resistance36 and was also found for clinical isolates of M. pneu-
moniae,24 although only limited data exist for in vivo-acquired
MLS resistance in Mycoplasma species.
Recently, resistance to macrolides and lincosamides has been
linked to modifications in the L4 and L22 rRNA-binding pro-
teins,13,23 especially in pneumococcal strains.6,9,13,19,23,27,31 In
the present studies, none of the variations in these proteins was
uniquely present in the resistant M. hyopneumoniae field iso-
late F19, and it is therefore unlikely that they are associated
with acquired resistance. This is in agreement with an earlier
report of resistant clinical strains of M. hominis and M. fer-
mentans.25
In in vitro experiments, resistance to tylosin was obtained in
M. hyopneumoniae strains after only seven or fewer passages
in selective media,15 indicating that acquired resistance due to
mutations of the 23S RNA may occur quite fast for bacteria
like M. hyopneumoniae, which only possess one copy of the
rRNA operon.30 The relation between the use of macrolides in
pig rearing and the occurrence of acquired resistance has been
indirectly demonstrated for M. hyosynoviae and other porcine
TABLE 2. MICS (G/ML) OF MLS-ANTIMICROBIAL AGENTS FOR BELGIAN M. hyopneumoniae FIELD ISOLATES AND THE
M. hyopneumoniae J REFERENCE STRAIN OBTAINED BY THE BROTH DILUTION TEST CARRIED OUT IN TWO-FOLD
MIC (g/ml)
Strain Azithromycin Tylosin Erythromycin Clarithromycin Clindamycin Lincomycin
F2 0.125a 0.03125 8 16 0.0625 0.25
F5 0.125–0.25 0.03125 8 16 0.125–0.25 0.25
F6 0.0625–0.125 0.03125 16 32 0.125 0.125
F18 0.0625 0.0625 32 32 0.125–0.25 0.125
F19 64 8–16 64 64 64 64
J 0.25 0.125 32 32 0.5 0.5
aOne value means that no difference between the repeated tests was observed.
bacteria.1,2,5 In contrast, the prevalence of acquired resistance
to macrolides for M. hyopneumoniae in the field is most likely
low.18,37 It is possible that resistant strains do not spread eas-
ily and that occurrence of resistance remains localized in an
area or even within a herd. Indeed, earlier RAPD data3 and our
own PFGE results (unpublished) show an enormous diversity
among isolates from different farms, suggesting that clones do
not readily spread in the environment, although further research
on this issue is needed. Because the type of resistance described
above is not encoded on a mobile element, and therefore not
transferable between different strains, the genetic stability of
the mutation may also be an important factor. Although the
A2058G transition has distinct advantages over the wild-type
in the presence of macrolides, the situation may be different in
the absence of the drugs.36 In any event, the emergence of this
resistance asks for a continuous monitoring, because it may
have important therapeutic implications in the treatment of my-
coplasma infections.
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